Skip to content

Immunovant, Inc. IMVT R&D credit carryforward

Discontinued — last reported Q4 '20

R&D credit carryforward at other companies

RBC Bearings logo
RBC BearingsRBC
$1.8M-91.6%
Our Bond, Inc.
 logo
Our Bond, Inc. OBAI
$350K+7.7%
General Mills logo
General MillsGIS
$305.5M+195%
Corvex
 logo
Corvex MOVE
$1.2M-60.0%
Immunovant, Inc. logo
Immunovant, Inc.IMVT
$53.7M+37.0%
Raytheon Technologies logo
Raytheon TechnologiesRTX
$963M+20.4%

Segments

By geography

See full
United States$53.7M+37.0%

Other financials

Income statement

See full
Net income-$147.9M-38.9%
EPS (diluted)-$0.73-15.9%

Balance sheet

See full
Cash & equivalents$902.1M+26.4%
Total debt$72.0K-26.5%
Total equity$852.6M+20.5%
Total assets$957.0M+23.3%

Cash flow

See full
Operating cash flow-$95.1M+14.1%
CapEx$8.0K-96.0%
Free cash flow-$95.1M+14.2%

Valuation

See full
Market cap$7.26B+74.2%
Enterprise value$6.35B+89.7%

Returns & leverage

See full
Return on equity-64.8%+2.5pp
Debt / equity0.0×
Current ratio9.1×-2.1×

Where this comes from

Reported directly by Immunovant, Inc. in its filing.

Tagged under the XBRL concept us-gaap:DeferredTaxAssetsTaxCreditCarryforwardsResearch.

The official record: Immunovant, Inc.’s 10-K, filed June 29, 2020, on SEC EDGAR. View the filing →